Safety and effectiveness of IV Thrombolysis in retinal artery occlusion: A multicenter retrospective cohort study
Open Access
- 1 December 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 8 (4) , 966-973
Abstract
Background: Retinal artery occlusion (RAO) may lead to irreversible blindness. For acute RAO, intravenous thrombolysis (IVT) can be considered as treatment. However, due to the rarity of RAO, data about IVT safety and effectiveness is limited. Methods: From the multicenter database ThRombolysis for Ischemic Stroke Patients (TRISP), we retrospectively analyzed visual acuity (VA) at baseline and within 3 months in IVT and non-IVT treated RAO patients. Primary outcome was difference of VA between baseline and follow up (∆VA). Secondary outcomes were rates of visual recovery (defined as improvement of VA ⩾ 0.3 logMAR), and safety (symptomatic intracranial hemorrhage (sICH) according to ECASS II criteria, asymptomatic intracranial hemorrhage (ICH) and major extracranial bleeding). Statistical analysis was performed using parametric tests and a linear regression model adjusted for age, sex and baseline VA. Results: We screened 200 patients with acute RAO and included 47 IVT and 34 non-IVT patients with complete information about recovery of vision. Visual Acuity at follow up significantly improved compared to baseline in IVT patients (∆VA 0.5 ± 0.8, p < 0.001) and non-IVT patients (∆VA 0.40 ± 1.1, p < 0.05). No significant differences in ∆VA and visual recovery rate were found between groups at follow up. Two asymptomatic ICH (4%) and one (2%) major extracranial bleeding (intraocular bleeding) occurred in the IVT group, while no bleeding events were reported in the non-IVT group. Conclusion: Our study provides real-life data from the largest cohort of IVT treated RAO patients published so far. While there is no evidence for superiority of IVT compared to conservative treatment, bleeding rates were low. A randomized controlled trial and standardized outcome assessments in RAO patients are justified to assess the net benefit of IVT in RAO.Keywords
Funding Information
- Swiss National Science Foundation (PP00P3_202663)
- Olga Mayenfish Foundation
- UZH Clinical Research Priority Program (CRPP) Stroke
- Swiss National Science Foundation (PP00P3_202663)
- Olga Mayenfish Foundation
- UZH Clinical Research Priority Program (CRPP) Stroke
This publication has 28 references indexed in Scilit:
- Intravenous Fibrinolytic Therapy in Central Retinal Artery OcclusionJAMA Neurology, 2015
- An Updated Definition of Stroke for the 21st CenturyStroke, 2013
- Symptomatic Intracranial Hemorrhage following Intravenous Thrombolysis for Acute Ischemic Stroke: A Critical Review of Case DefinitionsCerebrovascular Diseases, 2012
- Efficacy of Intravenous Tissue-Type Plasminogen Activator in Central Retinal Artery OcclusionStroke, 2011
- Central Retinal Artery Occlusion: Local Intra-arterial Fibrinolysis versus Conservative Treatment, a Multicenter Randomized TrialOphthalmology, 2010
- Intravenous Thrombolysis With Low-dose Recombinant Tissue Plasminogen Activator in Central Retinal Artery OcclusionAmerican Journal of Ophthalmology, 2008
- Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT)Graefe's Archive for Clinical and Experimental Ophthalmology, 2008
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Central retinal artery occlusion.Experimental Eye Research, 2004
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)The Lancet, 1998